ADC Therapeutics SA (ADCT)
| Market Cap | 442.63M +235.6% |
| Revenue (ttm) | 79.18M +4.4% |
| Net Income | -136.99M |
| EPS | -1.08 |
| Shares Out | 127.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,100,241 |
| Open | 3.500 |
| Previous Close | 3.500 |
| Day's Range | 3.455 - 3.710 |
| 52-Week Range | 1.254 - 4.980 |
| Beta | 1.84 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+129.89%) |
| Earnings Date | May 4, 2026 |
About ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue... [Read more]
Financial Performance
In 2025, ADC Therapeutics's revenue was $81.36 million, an increase of 14.85% compared to the previous year's $70.84 million. Losses were -$142.62 million, -9.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ADCT stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 129.89% from the latest price.
News
ADC Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 net product revenues rose 15% year-over-year to $20M, with stable demand for ZYNLONTA and reduced operating expenses. Key clinical milestones, including LOTIS-5 top-line data, are expected in 2026, with revenue growth acceleration projected for 2027.
ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year
Reports Q1 revenue $20.0M, consensus $19.99M. As of March 31, cash and cash equivalents were $231.0M vs. $261.3M as of December 31, 2025. The company has an expected cash runway…
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equiv...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that ...
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics Transcript: H.C. Wainwright Home Series
ZYNLONTA is positioned for significant growth, with pivotal LOTIS-5 and LOTIS-7 trial data expected in 2024. Expansion into second-line DLBCL and indolent lymphomas could drive peak sales to $600M–$1B, supported by a strong cash position and strategic flexibility.
ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on ADC Therapeutics (ADCT) to $8 from $7 and keeps a Buy rating on the shares. The firm updated the…
ADC Therapeutics files to sell 9.83M common shares for holders
17:10 EDT ADC Therapeutics (ADCT) files to sell 9.83M common shares for holders
ADC Therapeutics Earnings Call Transcript: Q4 2025
ZYNLONTA revenues grew in Q4 2025, with stable annual sales and reduced operating expenses. Strategic focus on expanding indications and strong cash position support long-term growth, with key clinical data readouts expected in 2026 and 2027.
ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)
Reports Q4 revenue $23.06M, consensus $22.29M. “Building off the meaningful progress achieved across our ZYNLONTA clinical program in DLBCL and through investigator-initiated trials in indolent lympho...
ADC Therapeutics sees cash runway at least into 2028
Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases s...
ADC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
ZYNLONTA is positioned for significant growth with pivotal phase III and combination study data expected this year, targeting both complex and broadly accessible DLBCL segments. Early results show high response rates and manageable safety, with expansion into indolent lymphomas and second-line settings projected to drive revenue growth to $600 million–$1 billion.
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics to Participate in March Investor Conferences
LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced par...
ADC Therapeutics announces amended HealthCare Royalty financing agreement
ADC Therapeutics (ADCT) has entered into an amendment to its royalty purchase agreement with entities managed by HealthCare Royalty. Based on confidence in the long-term outlook for Zynlonta, ADC Ther...
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha...
ADC Therapeutics participates in a conference call with Cantor
Analyst Schmidt holds a conference call with CEO Mallik on February 6 at 1 pm hosted by Cantor.Webcast Link
ADC Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Zynlonta is expanding from third line DLBCL into earlier lines and indolent lymphomas, with pivotal LOTIS-5 and LOTIS-7 trials expected to drive significant revenue growth from 2027. Strong efficacy, rapid response, and a favorable safety profile position it competitively in both complex and broadly accessible therapy segments.
ADC Therapeutics sees FY25 net product revenue $73M
FY25 revenue consensus $76.6M. “During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028,” said Ameet Mallik, CEO of…
ADC Therapeutics sees Q4 net product revenue $22M
Q4 revenue consensus $18.29M.
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provi...
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics Transcript: Study Update
Updated LOTIS-7 data show ZYNLONTA plus glofitamab achieved an 89.8% ORR and 77.6% CR rate in second-line plus DLBCL, with durable responses and a manageable safety profile. Lower CRS rates and strong efficacy in relapsed and refractory patients support further development.